Form D · Biotechnology
VOLITIONRX LTD
Henderson, NV · CIK 0000093314
Offering snapshot reported Jan 28, 2026 · SEC filing
- Reported sold
- $22.7M Offering amount: $22.7M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- May 20, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 28, 2026 | Amendment | $22,650,000 | No comparison | 1 | SEC filing |
| May 30, 2025 | Initial | $16,250,000 | No comparison | 1 | SEC filing |
| Mar 26, 2024 | Initial | $100,000 | No comparison | 1 | SEC filing |
| Aug 27, 2018 | Initial | $24,000,000 | No comparison | 1 | SEC filing |
| Nov 21, 2014 | Initial | $721,849 | No comparison | 21 | SEC filing |
| Oct 14, 2014 | Initial | $229,393 | No comparison | 10 | SEC filing |
| Oct 14, 2014 | Initial | $750,000 | No comparison | 23 | SEC filing |
| Sep 25, 2014 | Initial | $1,189,749 | No comparison | 7 | SEC filing |
| Mar 11, 2014 | Initial | $3,000,000 | No comparison | 24 | SEC filing |
| Dec 3, 2013 | Initial | $934,923 | No comparison | 7 | SEC filing |
| Jun 14, 2013 | Initial | $595,000 | No comparison | 27 | SEC filing |
| May 8, 2013 | Initial | $416,000 | No comparison | 8 | SEC filing |
| Mar 27, 2013 | Initial | $489,583 | No comparison | 19 | SEC filing |
| Jul 26, 2012 | Initial | $1,204,152 | No comparison | 33 | SEC filing |
| Oct 28, 2011 | Initial | $1,727,163 | No comparison | 38 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-547712
The Total Offering Amount consists of two separate closings including $6,400,000 in the additional closing held in January 2026 and assumes full exercise of the issued Warrants.
Source: Form D, filed Jan 28, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kevin John Alexander | Director |
| Phillip Barnes | Director |
| Louise Batchelor | Executive |
| Salvatore Thomas Butera | Executive |
| Alan Colman | Director |
| Martin Charles Faulkes | Director, Executive |
| Gael Forterre | Executive |
| Edward Futcher | Director |
| Mickie Henshall | Director |
| Terig Hughes | Executive |
| Guy Archibald Innes | Director |
| Jasmine Kway | Executive |
| Malcolm Lewin | Executive |
| Jacob Micallef | Executive |
| Gaetan Michel | Executive |
| Kim Nguyen | Director |
| Mike O'connell | Executive |
| Nicholas Plummer | Executive |
| Andrew Retter | Executive |
| Cameron Reynolds | Director, Executive |
| Rodney Rootsaert | Executive |
| Ethel Rubin | Director |
| Habib Skaff | Director |
| Timothy I Still | Director |
| Jason Terrell | Executive |
| Satu Vainikka | Director |
| David Cecil Vanston | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1489 West Warm Springs Road, Suite 110
Henderson, NV, 89014
Henderson, NV, 89014